相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
Thomas L. Andersen et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects-polish multicenter experience
Jolanta Kunikowska et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Radiometals for imaging and theranostics, current production, and future perspectives
Renata Mikolajczak et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2019)
Neuroendocrine Tumor Therapy: Lu-177-DOTATATE
Erik S. Mittra
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
Nader Hirmas et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
The theranostic promise for Neuroendocrine Tumors in the late 2010s-Where do we stand, where do we go?
Rudolf A. Werner et al.
THERANOSTICS (2018)
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Murat Fani Bozkurt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging
Tobias Baumann et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates
Chunlei Wang et al.
JOURNAL OF CHROMATOGRAPHY A (2016)
Comparison between Three Promising β-emitting Radionuclides, 67Cu, 47Sc and 161Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
Christophe Champion et al.
THERANOSTICS (2016)
[Lu-177-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide (Lu-177-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
Richard P. Baum et al.
THERANOSTICS (2016)
NEN - the role of somatostatin receptor scintigraphy in clinical setting
Marta Opalinska et al.
NUCLEAR MEDICINE REVIEW (2016)
68Ga-Based Radiopharmaceuticals: Production and Application Relationship
Irina Velikyan
MOLECULES (2015)
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
A. Romer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions
Mattia Asti et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90
Anna Nardelli et al.
APPLIED RADIATION AND ISOTOPES (2011)
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Jolanta Kunikowska et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT?
J. P. Esser et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
CRITICAL EVALUATION OF STABILITY CONSTANTS OF METAL COMPLEXES OF COMPLEXONES FOR BIOMEDICAL AND ENVIRONMENTAL APPLICATIONS (IUPAC Technical Report)
Giorgio Anderegg et al.
PURE AND APPLIED CHEMISTRY (2005)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
M de Jong et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
G Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
分享论文
